Document Detail

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
MedLine Citation:
PMID:  23135778     Owner:  NLM     Status:  Publisher    
Introduction As angiogenic pathways have become important targets for inhibition of tumor growth, we examined the concept of dual pathway blockade by small-molecule tyrosine kinase inhibitors targeting vascular endothelial and epidermal growth factor receptors. Methods Escalating doses of pazopanib (400-800 mg once daily [QD]) plus erlotinib (100-150 mg QD) doses were evaluated in cohorts of 3-6 adults with advanced solid tumors. Twelve additional patients were enrolled in an expansion cohort to confirm the maximum tolerated dose (MTD). Results The MTD, defined during assessment of 20 patients, was pazopanib 600 mg plus erlotinib 150 mg. Two dose-limiting toxicities, rash and elevated liver enzymes, occurred at pazopanib 800 mg and erlotinib 150 mg. Overall, 30 % and 27 % of patients required dose interruption of pazopanib or erlotinib, respectively; 15 % of patients required a dose reduction of erlotinib to manage toxicities. The most common adverse events in patients treated with any dose regimen of pazopanib plus erlotinib (N = 33) were diarrhea, rash, nausea, and decreased appetite. The adverse-event profile of the combination did not appear to differ from that of each compound administered alone. Coadministration of pazopanib 600 mg QD and erlotinib 150 mg QD did not consistently affect the pharmacokinetics of either compound relative to that observed for either compound administered alone. Of 26 patients evaluated for efficacy, 3 (12 %; all non-small-cell lung cancer) had partial response and 10 (38 %) had stable disease. Conclusions Concomitant administration of pazopanib 600 mg and erlotinib 150 mg is feasible, with a manageable toxicity profile. These results support further clinical development of the pazopanib-erlotinib combination.
Grace K Dy; Jeffrey R Infante; S Gail Eckhardt; Silvia Novello; Wen Wee Ma; Suzanne F Jones; Anne Huff; Qiong Wang; A Benjamin Suttle; Lone H Ottesen; Alex A Adjei; Howard A Burris
Related Documents :
24895078 - Prednisone has no effect on the pharmacokinetics of cyp3a isozyme-metabolized drugs - m...
24977458 - Low-dose transdermal estradiol for vasomotor symptoms: a systematic review.
12695418 - Pde5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers.
12757838 - Effects of nicotine on target biting and resident-intruder attack.
1902408 - A long-term dose-response study of somatostatin analogue (sms 201-995, octreotide) in r...
3687588 - Rev 5901 and ly 171,883 protect rat gastric mucosa against ethanol-induced damage.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-8
Journal Detail:
Title:  Investigational new drugs     Volume:  -     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Shunt survival rates by using the adjustable differential pressure valve combined with a gravitation...
Next Document:  Determinants of patient screen failures in Phase 1 clinical trials.